Furthermore, immune checkpoint inhibition has been studied in detail to explore the relevant mechanisms of PD-1/PD-L1 and CTLA-4, but specific useful ICB targets have not produced reflected a relatively ideal effect in HCC treatment. Here, PDCD1 is linked to hepatocellular carcinoma.